The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.
The industry feels that prices of active pharmaceutical ingredients (APIs) can go up in the range of 5-15 per cent.
Honda has invested Rs 3,526 crore in its Rajasthan unit.
The NPPA letter was issued to GSK on Wednesday.
Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
.jpg)
What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.
Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.
Maruti Suzuki is keen that the Gujrat government revises payment condition in the agreement it signed with the former for setting up a plant in Hansalpur.
The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
CCI has accused realty player DLF of preparing one-sided agreement with home buyers
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Development in state has benefitted community, they say.
Formal announcement of venture into new segment on Thursday; group's entry timely, given the demand, say experts
Maruti Suzuki signed a State Support Agreement with the Gujarat government in June 2012 for buying land and setting up a factory
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
While tukkal salers claim that their business has doubled this season, kite makers and retailers say that business has been down by around 25 per cent.
Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances